|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, ERK5 knockdown strongly radiosensitized A549 and LLC tumor xenografts to inhibition, with a higher apoptotic response and reduced tumor neovascularization.
|
30804322 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In particular, it has been reported that ERK5 is a key signaling molecule involved in almost all the biological features of cancer cells so that its targeting is emerging as a promising strategy to suppress tumor growth and spreading.
|
30901834 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DUSP6/MKP3 is a dual-specific phosphatase that regulates extracellular regulated kinase ERK1/2 and ERK5 activity, with an increasingly recognized role as tumor suppressor.
|
31027181 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition.
|
29507229 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, the administration of miR-200b induced a remarkably tumor regression in vivo and reduced the effect of TGF-β-related EMT in AP-2α and MAPK7-dependent manner.
|
29084594 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VEGF has prognostic value in clear cell renal cell carcinoma, and ERK5 may be a new prognostic marker in this type of tumor owing to its relationship with metastasis and more advanced stages.
|
27836247 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis.
|
27735944 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Whereas TH levels were correlated with ERK5 levels in normal adrenal medullas, ERK5 was down-regulated and TH was up-regulated in pheochromocytomas, indicating that TH levels are regulated by alternative mechanisms in tumors.
|
26739108 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we investigated the interplay between RAS-RAF-MEK-ERK and ERK5 signaling and studied the role of ERK5 in tumor cell proliferation in 2 disease-relevant cell models.
|
26959608 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggested that MEK5/ERK5/NF-κB signalling pathway is important for tumour onset, progression and metastasis, possibly representing a novel relevant therapeutic target in colon cancer treatment.
|
25855966 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Considering that ERK5 is expressed in almost all tumor types, our findings suggest that targeting tumor-associated inflammation via anti-ERK5 therapy may have broad implications for the treatment of human tumors.
|
25649771 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ERK5 regulates the biology of HCC cells and modulates tumour development and growth in vivo.
|
25183205 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Most importantly, injection of shERK5 malignant mesothelioma cell lines into SCID mice showed significant reduction in tumor growth using both subcutaneous and intraperitoneal models.
|
23446998 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, our results provide new biochemical data suggesting that ERK5 is a novel target of the tumor suppressor VHL, opening a new field of research on the role of ERK5 in renal carcinomas.
|
23730213 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)-extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (CaP).
|
23321517 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As well as playing a key role in endothelial cell survival and tubular morphogenesis during tumour neovascularization, ERK5 is also emerging as a regulator of tumour cell invasion and migration.
|
22260700 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Forced expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in concert with miR-145 in gut tumors of Apc(Min) mice.
|
22876303 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)-extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (PCa).
|
21266977 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of BMK1 by XMD8-92 blocked tumor cell proliferation in vitro and significantly inhibited tumor growth in vivo by 95%, demonstrating the efficacy and tolerability of BMK1-targeted cancer treatment in animals.
|
20832753 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An increase in MAPK7 copy number was detected in 35 of 66 primary HCC tumors.
|
18973138 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We obtained the following in vitro and in vivo evidence to support the above expression data: (1) cotransfection of ERK5wt and MEK5D constructs in PC3 cells results in predominant ERK5 nuclear localization, similar to that observed in aggressive clinical disease; (2) ERK5-overexpressing PC3 cells have enhanced proliferative, migrative and invasive capabilities in vitro (P<0.0001), and were dramatically more efficient in forming tumors, with a shorter mean time for tumors to reach a critical volume of 1000 mm(3), in vivo (P<0.0001); (3) the MEK1 inhibitor, PD184352, blocking ERK1/2 activation at low dose, did not suppress proliferation but did significantly decrease proliferation at a higher dose required to inhibit ERK5 activation.
|
18071319 |
2008 |